Primary Tumor Burden Score: A Novel Staging Parameter Superior to ypT-category for Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy
Sponsor study identifier
observational
187
0 countries
N/A
Study Start
May 21, 2010
Actual (reported)Primary Completion
December 1, 2021
Actual (reported)Study Completion
March 15, 2023
Actual (reported)In this case-only study, the investigators try to define a novel staging parameter, the Primary Tumor Burden Score (PTBS).
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 15, 2023
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 21, 2010
Actual (reported)December 1, 2021
Actual (reported)March 15, 2023
Actual (reported)March 29, 2023
Actual (reported)May 3, 2023
Actual (reported)Five-year survival of patients
The survival of the patients was recorded by follow-up for five years after surgery.
From surgery to the end of follow-up(at least 5 years later)
Training cohort will be used to find the best calculation and cut-off values for PTBS in ESCC after nCRT.
The study's conclusion will be verified in Zhongshan Hospital Xiamen branch.
ESCC patients that recieved surgery and nCRT.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Patients with ESCC undergoing nCRT at the Department of Thoracic Surgery, Zhongshan Hospital of Fudan University (training cohort), and the Department of Thoracic Surgery, Zhongshan Hospital Xiamen Branch (validation cohort), between January 2010 and February 2019 were reviewed. The inclusion criteria were (I) thoracic ESCC; (II) McKeown or Ivor-Lewis transthoracic approach; (III) locally advanced resectable tumor with cT3-4aNany staging treated with nCRT; (IV) no history of concomitant or prior malignancy.
Huang X, Jiang D, Sun T, Zhou G, Zeng Z, Zhang S, Lin M, Fan H, Jian Z, You R, Liu F, Wu M, Xu W, Tang H, Hou Y, Tan L. Primary Tumour Burden Score: A Novel Staging Parameter for Oesophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy. Eur J Cardiothorac Surg. 2025 Sep 2;67(9):ezaf254. doi: 10.1093/ejcts/ezaf254.
Patients' pathological sections
187 participants (actual enrollment reported by the registry).
First Submitted
March 29, 2023
First Posted
May 3, 2023
Study Start
May 21, 2010
Actual (reported)Contact the study team to confirm eligibility.
Primary Completion
December 1, 2021
Actual (reported)Study Completion
March 15, 2023
Actual (reported)Last Updated
May 3, 2023
Record last verified: 2023-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: